| Zhang, Li |
NCT05138705: Clinical Trial of Quadrivalent Influenza Virus Split Vaccine in Population Aged 3-8 Years |
|
|
| Completed | 4 | 380 | RoW | Quadrivalent Influenza Virus Split Vaccine | Shanghai Institute Of Biological Products | Influenza, Human | 02/22 | 08/22 | | |
NCT05329038: Immunogenicity，Safety and Cross - Immune Response With Mutant Strains of a Third Dose of an Inactivated COVID-19 Vaccine |
|
|
| Active, not recruiting | 4 | 180 | RoW | Inactivated COVID-19 Vaccine, CoronaVac | Sinovac Life Sciences Co., Ltd. | COVID-19 | 06/22 | 02/24 | | |
NCT04624854: Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD) |
|
|
| Active, not recruiting | 4 | 8250 | RoW | Clopidogrel and Aspirin dual-antiplatelet therapy, Aspirin monotherapy | Harbin Medical University, Chinese Society of Cardiology, Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Artery Disease, Myocardial Ischemia, Acute Coronary Syndrome, Heart Diseases, Syndrome Heart Disease, Cardiovascular Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Coronary Disease, Vascular Diseases | 04/25 | 04/25 | | |
OFFER, NCT04536558: Olanzapine Plus Fosaprepitant Standard Antiemetic Therapy in the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients Receiving High Emetic Risk Multi-day Chemotherapy: a Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study |
|
|
| Not yet recruiting | 3 | 352 | RoW | olanzapine plus fosaprepitant-based triple regimen, placebo plus fosaprepitant-based triple regimen | Sun Yat-sen University, Jiangsu Hansoh Pharmaceutical Co., Ltd. | Solid Tumor Patients Receiving High Emetic Risk Multi-day Chemotherapy | 02/21 | 03/21 | | |
NCT04550949: To Evaluate the Efficacy and Safety of QL1206 and Xgeva in Patients With Bone Metastases From Solid Tumors |
|
|
| Recruiting | 3 | 700 | RoW | QL1206, recombinant human anti-RANKL monoclonal antibody injection, Xgeva, Denosumab Injection | Qilu Pharmaceutical Co., Ltd. | Bone Metastases | 03/21 | 06/22 | | |
RATIONALE 309, NCT03924986: Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer |
|
|
| Completed | 3 | 263 | RoW | Tislelizumab, BGB-A317, Placebo, Gemcitabin, Cisplatin | BeiGene | Recurrent or Metastatic Nasopharyngeal Cancer | 03/21 | 12/23 | | |
|
|
|
|
|
NCT03707509: Phase III Study of Camrelizumab in Combination With Chemotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma |
|
|
| Active, not recruiting | 3 | 263 | RoW | Camrelizumab, SHR-1210, Placebos, Placebo - Concentrate, Gemcitabine, Gemcitabine Hydrochloride for Injection, Cisplatin, Cisplantin Injection | Jiangsu HengRui Medicine Co., Ltd. | Nasopharyngeal Carcinoma | 08/21 | 12/22 | | |
| Recruiting | 3 | 315 | RoW | TQB2450, Anlotinib, TQB2450(blank), Anlotinib(blank) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Stage III Non-small-cell Lung Cancer | 12/22 | 03/25 | | |
ORIENT-11, NCT03607539: Efficacy and Safety Evaluation of Sintilimab in Patients With Advanced or Metastatic Non-squamous NSCLC |
|
|
| Completed | 3 | 397 | RoW | Sintilimab, IBI308, Pemetrexed, Platinum, Placebos | Innovent Biologics (Suzhou) Co. Ltd. | Lung Neoplasms | 02/23 | 02/23 | | |
|
|
|
|
|
|
|
PROFIT, NCT05509634: Clinical Study of HR20013 for Injection in Patients With Malignant Solid Tumors |
|
|
| Completed | 3 | 754 | RoW | HR20013 for injection；dexamethasone, fosaprepitant dimeglumine for injection；palonosetron hydrochloride injection；dexamethasone | Fujian Shengdi Pharmaceutical Co., Ltd. | Prevention of Nausea and Vomiting Caused by Highly Emetogenic Chemotherapy | 06/23 | 08/23 | | |
NCT05683600: Efficacy and Safety of COVID-19 Vaccine as Booster Vaccination in Adults 18 Years of Age or Older |
|
|
| Terminated | 3 | 3000 | RoW | Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001, Placebo | Guangzhou Patronus Biotech Co., Ltd., Yantai Patronus Biotech Co., Ltd. | COVID-19 | 07/23 | 07/23 | | |
NCT04951648: A Phase III Study to Assess the Efficacy and Safety of Almonertinib Versus Platinum-based Chemotherapy as First-line Therapy in Patients With Locally Advanced or Metastatic NSCLC Harbouring Uncommon EGFR Mutation |
|
|
| Not yet recruiting | 3 | 220 | RoW | Almonertinib, HS-10296, chemotherapy | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Non-small Cell Lung Cancer | 10/23 | 09/24 | | |
NCT05525637: Safety and Efficacy Study of YZJ-1139 in Insomnia Disorder |
|
|
| Recruiting | 3 | 1041 | RoW | YZJ-1139 20mg, YZJ-1139 40mg, Placebo | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | Insomnia Disorder | 12/24 | 12/24 | | |
NCT06380348: JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations |
|
|
| Not yet recruiting | 3 | 398 | NA | JMT101 Injection, Osimertinib tablet, Cisplatin injection, Pemetrexed injection | Shanghai JMT-Bio Inc. | Local Advanced or Metastatic NSCLC | 03/27 | 03/28 | | |
BL-B01D1-301, NCT06382116: A Study Comparing BL-B01D1 With Platinum Based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer |
|
|
| Recruiting | 3 | 428 | RoW | BL-B01D1, Pemetrexed+Cisplatin or Carboplatin | Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Non-small Cell Lung Cancer | 05/26 | 05/26 | | |
| Recruiting | 3 | 652 | RoW | BL-B01D1, Topotecan | Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Small Cell Lung Cancer | 07/26 | 07/26 | | |
NCT06554184: HR20013 for Nausea and Vomiting Associated With Moderate Emetic Risk Anticancer Agents |
|
|
| Recruiting | 3 | 700 | RoW | HR20013 + dexamethasone + palonosetron placebo, Palonosetron + dexamethasone + HR20013 placebo | Fujian Shengdi Pharmaceutical Co., Ltd. | Nausea and Vomiting Associated With Moderate Emetic Risk Anticancer Agents | 09/25 | 09/25 | | |
NCT06735391: A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations |
|
|
| Recruiting | 3 | 516 | RoW | JMT101, Recombinant Humanized Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Injection, Osimertinib | Shanghai JMT-Bio Inc. | Locally Advanced or Metastatic Non-squamous NSCLC, Harboring EGFR Sensitive Mutations NSCLC, Previously Untreated Systematically NSCLC | 09/26 | 05/29 | | |
NCT06082635: TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC) |
|
|
| Recruiting | 3 | 297 | RoW | TGRX-326, TGRX-326 QD (once a day), Crizotinib, Crizotinib 250 mg BID (twice a day) | Shenzhen TargetRx, Inc., Sun Yat-sen University | Non Small Cell Lung Cancer | 12/24 | 11/28 | | |
| Active, not recruiting | 3 | 322 | RoW | Ivonescimab (SMT112 or AK112) Injection, Pemetrexed, Carboplatin, Placebo Injection | Akeso, Akeso | Non-Squamous Non-small Cell Lung Cancer | 06/24 | 11/25 | | |
| Recruiting | 3 | 356 | RoW | SKB264, Pemetrexed, Carboplatin, Cisplatin | Sichuan Kelun Pharmaceutical Research Institute Co., Ltd., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Non-small Cell Lung Cancer | 05/25 | 09/26 | | |
| Not yet recruiting | 3 | 650 | NA | QL1706, PSB205, Tilesizumab, BGB-108 | Qilu Pharmaceutical Co., Ltd. | Lung Cancer | 06/25 | 06/25 | | |
NCT05767892: YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations |
|
|
| Not yet recruiting | 3 | 350 | RoW | YK-209A tablet, Pemetrexed+carboplatin/Cisplatin | Suzhou Puhe Pharmaceutical Technology Co., LTD | Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | 07/25 | 12/26 | | |
NCT06118333: A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma |
|
|
| Recruiting | 3 | 368 | RoW | BL-B01D1, capecitabine, gemcitabine, docetaxel | Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Nasopharyngeal Carcinoma | 12/25 | 12/25 | | |
NCT05943795: A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell Carcinoma |
|
|
| Recruiting | 3 | 584 | RoW | SI-B001, Docetaxel | Sichuan Baili Pharmaceutical Co., Ltd. | Non-small Cell Lung Adenocarcinoma, Squamous Cell Carcinoma of Lung | 07/26 | 07/26 | | |
NCT06319313: Efficacy and Safety of JMT101 Combined Wth Docetaxel / HB1801 in Patients With Squamous Cell Non-Small Cell Lung Cancer |
|
|
| Not yet recruiting | 2/3 | 534 | NA | JMT101, docetaxel, HB1801 | Shanghai JMT-Bio Inc. | Squamous Cell Non-small Cell Lung Cancer | 07/26 | 12/27 | | |
NCT05020769: SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer. |
|
|
| Recruiting | 2/3 | 14 | RoW | SI-B001, Osimertinib | Sichuan Baili Pharmaceutical Co., Ltd. | Non-small Cell Lung Cancer | 06/25 | 06/25 | | |
DUBHE-N-302, NCT05576272: A Phase II/III Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Nasopharyngeal Carcinoma |
|
|
| Active, not recruiting | 2/3 | 460 | RoW | QL1706, Carrelizumab, Gemcitabine, Cisplatin | Qilu Pharmaceutical Co., Ltd. | Nasopharyngeal Carcinoma | 12/24 | 12/24 | | |
NCT03215693: X-396 Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib |
|
|
| Active, not recruiting | 2 | 152 | RoW | X-396 capsule, Ensartinib | Betta Pharmaceuticals Co., Ltd. | Non-Small Cell Lung Cancer | 03/20 | 12/23 | | |
JMT101-CSP-005, NCT06391944: JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common Mutations |
|
|
| Active, not recruiting | 2 | 161 | RoW | JMT101 Injection, Osimertinib tablet | Shanghai JMT-Bio Inc. | Local Advanced or Metastatic NSCLC, Harboring EGFR Common Mutation | 05/23 | 11/26 | | |
| Recruiting | 2 | 54 | RoW | KN046 (Recombinant Humanized PD-L1/CTLA-4 Bispecific Single Domain Antibody Fc Fusion Protein Injection), Axitinib | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Advanced Non-small Cell Lung Cancer | 05/27 | 12/27 | | |
NCT05702268: Pharmacodynamic Blood Characteristics of ICP-332 in Patients With Moderate to Severe Atopic Dermatitis |
|
|
| Recruiting | 2 | 75 | RoW | ICP-332, ICP-332 Placebo | Beijing InnoCare Pharma Tech Co., Ltd. | Moderate to Severe Atopic Dermatitis | 07/23 | 12/23 | | |
BECOME, NCT05132777: Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Non-Small Cell Lung Cancer |
|
|
| Not yet recruiting | 2 | 155 | NA | JMT101, Osimertinib Mesylate Tablets | Shanghai JMT-Bio Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Locally Advanced or Metastatic Non-Small Cell Lung Cancer, EGFR Exon20 Insertion Mutations | 09/23 | 09/24 | | |
NCT05068427: Trial of Chidamide in Combination With Envafolimab in Patients With PD-1 Inhibitor Resistant Advanced NSCLC. |
|
|
| Completed | 2 | 34 | RoW | Chidamide, CS055, Envafolimab, KN035 | Chipscreen Biosciences, Ltd. | Non Small Cell Lung Cancer | 02/23 | 05/24 | | |
NCT05020457: SI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC. |
|
|
| Recruiting | 2 | 60 | RoW | SI-B001, AP or TP, AP chemotherapy regimen was pemetrexed combined with cisplatin, and TP chemotherapy regimen was paclitaxel combined with cisplatin., Docetaxel | Sichuan Baili Pharmaceutical Co., Ltd. | Non Small Cell Lung Cancer | 06/25 | 06/25 | | |
NCT04844970: Anamorelin Study for Advanced Pancreatic Cancer |
|
|
| Recruiting | 2 | 100 | US | Anamorelin Hydrochloride, Placebo | Lahey Clinic, Helsinn Healthcare SA, Quartesian LLC | Metastatic Pancreatic Cancer | 12/24 | 12/24 | | |
NCT05955391: TGRX-326 Chinese Phase II for Advanced Non-small Cell Lung Cancer (NSCLC) |
|
|
| Recruiting | 2 | 157 | RoW | TGRX-326 | Shenzhen TargetRx, Inc., Sun Yat-sen University, Tongji Hospital, Sichuan Cancer Hospital and Research Institute, The First Affiliated Hospital of Zhengzhou University, West China Hospital, Zhejiang University, Jilin Provincial Tumor Hospital, Hunan Cancer Hospital, Shandong Cancer Hospital and Institute, Jiangxi Provincial Cancer Hospital, First Hospital of China Medical University, The Affiliated Hospital of Qingdao University, Liaoning Tumor Hospital & Institute, Haerbin Medical University Cancer Hospital, Xinxiang Central Hospital, Xiangyang Central Hospital, Mianyang Central Hospital, Zhejiang Cancer Hospital, Henan Cancer Hospital, First Affiliated Hospital, Sun Yat-Sen University, First Affiliated Hospital of Bengbu Medical College, Chinese Academy of Medical Science Cancer Hospital, Shenzhen Center, Bingzhou Medical University Affiliated Hospital, Fujian Cancer Hospital, Ningbo No. 1 Hospital, First Affiliated Hospital Xi'an Jiaotong University, The Second Affiliated Hospital of AFMU, Yunnan Cancer Hospital, Capital Medical School Beijing Chest Hospital, Shijiazhuang People's Hospital, Tianjin Cancer Hospital, Affiliated Cancer Hospital of Guizhou Medical University, Nanchang University First Affiliated Hospital, Jingzhou First People's Hospital, Shanghai Chest Hospital | Non-small Cell Lung Cancer | 02/24 | 08/24 | | |
AK112-201, NCT04736823: A Trial of AK112 (PD1/VEGF Bispecific) in Combination With Chemotherapy in Patients With NSCLC |
|
|
| Recruiting | 2 | 296 | RoW | AK112, Pemetrexed, Paclitaxel, Carboplatin, Docetaxel | Akeso | NSCLC | 12/24 | 03/25 | | |
NCT05970432: A Clinical Study of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis |
|
|
| Recruiting | 2 | 160 | RoW | TQH2722 injection 300mg-150mg, TQH2722 injection 600mg-300mg, TQH2722 injection 900mg-450mg, TQH2722 injection matching Placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Atopic Dermatitis | 03/24 | 03/24 | | |
BL-B01D1-204-05, NCT06475300: A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors |
|
|
| Recruiting | 2 | 332 | RoW | BL-B01D1, PD-1 Monoclonal Antibody | Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma, Solid Tumor | 07/26 | 07/26 | | |
NCT05513573: Phase II Clinical Study to Compare the Efficacy and Safety of HLX07 + Serplulimab +Chemotherapy Versus Placebo + Serplulimab + Chemotherapy in First-Line Treatment of Patients With Recurrent or Metastatic NPC |
|
|
| Active, not recruiting | 2 | 75 | RoW | HLX07, HLX10, placebo, chemotherapy | Shanghai Henlius Biotech | Nasopharyngeal Carcinoma by AJCC V8 Stage | 09/24 | 09/26 | | |
NCT06514027: Study of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion Mutations |
|
|
| Not yet recruiting | 2 | 30 | RoW | BEBT-109 Capsules, KCBT-1083, Pemetrexed Disodium for Injection, Carboplatin Injection, Cisplatin Injection | BeBetter Med Inc | Non Small Cell Lung Cancer | 06/27 | 11/27 | | |
| Recruiting | 2 | 270 | RoW | TQB2102 for injection, TQB2102 for injection combined with Benmelstobart injection | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Non-Small Cell Lung Cancer | 10/25 | 02/26 | | |
NCT04992858: Ningetinib in Advanced NSCLC Skipping Mutations With MET Exon 14 Skipping Mutations |
|
|
| Not yet recruiting | 2 | 80 | NA | CT053PTSA, Ningetinib | Sunshine Lake Pharma Co., Ltd. | Advanced NSCLC | 09/24 | 12/24 | | |
JSKN016-201, NCT06775483: Evaluation of JSKN016 in the Treatment of Advanced Non-small Cell Lung Cance： a Phase II Clinical Study |
|
|
| Not yet recruiting | 2 | 220 | NA | JSKN016, Docetaxel | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Advanced Non-small Cell Lung Cancer | 06/27 | 11/27 | | |
FOCUS-C, NCT05334277: Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA |
|
|
| Recruiting | 2 | 280 | RoW | Furmonertinib, AST2818, Furmonertinib/Pemetrexed/Carboplatin, Furmonertinib/Pemetrexed/Carboplatin/Bevacizumab | Sun Yat-sen University, Allist Pharmaceuticals, Inc., GeneCast Biotechnology Co., Ltd. | Non-small Cell Lung Cancer | 02/25 | 02/28 | | |
OCEANII, NCT05195632: Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients with Metastatic Non-Small Cell Lung Cancer |
|
|
| Active, not recruiting | 2 | 63 | RoW | Encorafenib, PF-07263896 or W0090 (in Europe), LGX818 (in US), ONO-7702 (in Japan), Binimetinib, W0074 (in Europe), MEK162 (in US), ARRY-438162 (in US), ONO-7703 (in Japan) | Pierre Fabre Medicament | Non-Small Cell Lung Cancer | 05/25 | 05/25 | | |
NCT05956587: A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors |
|
|
| Recruiting | 2 | 121 | RoW | BL-B01D1, SI-B003 | Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma | 11/25 | 11/25 | | |
NCT05588609: Study Evaluating Zenocutuzumab in Patients with or Without Molecularly Defined Cancers |
|
|
| Active, not recruiting | 2 | 90 | US | Afatinib Oral Tablet, GILOTRIF®, GIOTRIF®, Enzalutamide Pill, XTANDI®, Abiraterone acetate tablets, ZYTIGA®, MCLA-128, Zenocutuzumab | Merus N.V. | NSCLC Harboring NRG1 Fusion, Metastatic Castration-resistant Prostate Cancer | 10/25 | 03/26 | | |
SKB264-II-04, NCT05816252: A Study of SKB264 for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) |
|
|
| Recruiting | 2 | 498 | Europe, RoW | SKB264, MK-2870, Pembrolizumab, MK-3475, Carboplatin, Carboplatin for injection, Osimertinib, Osimertinib Mesylate | Klus Pharma Inc., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Non-small Cell Lung Cancer | 12/25 | 10/26 | | |
| Not yet recruiting | 1/2 | 30 | RoW | SHR-1701, SHR-1701 Injection, Famitinib, SHR-1020 | Jiangsu HengRui Medicine Co., Ltd. | Nasopharyngeal Carcinoma | 05/22 | 02/24 | | |
TQB2858-Ib-01, NCT05198531: To Evaluate the Safety and Efficacy of TQB2858 Injection to the Subjects With Recurrent/Metastatic Nasopharyngeal Cancer |
|
|
| Recruiting | 1/2 | 90 | RoW | TQB2858 Injection, Anlotinib Hydrochloride Capsule, Gemcitabine hydrochloride injection, Cisplatin Injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Recurrent / Metastatic Nasopharyngeal Cancer | 10/22 | 08/23 | | |
| Recruiting | 1/2 | 280 | RoW | SAF-189s, foritinib succinate | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Advanced Cancer, Advanced Solid Tumor, Lung Cancer, Nonsmall Cell | 12/22 | 03/26 | | |
AK104-207, NCT04647344: A Study of AK104 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer |
|
|
| Completed | 1/2 | 46 | RoW | AK104 plus Carboplatin and Pemetrexed, AK104 plus Carboplatin and paclitaxel | Akeso | Lung Cancer Non-Small Cell Stage IIIB/IIIC/IV | 12/23 | 12/23 | | |
NCT04775680: Study of ADG106 In Combination With PD-1 Antibody In Advanced or Metastatic Solid Tumors and/or Non Hodgkin Lymphoma |
|
|
| Terminated | 1/2 | 25 | RoW | ADG106 injection, PD-1 antibody injection | Adagene (Suzhou) Limited | Solid Tumor, Non Hodgkin Lymphoma | 02/23 | 02/23 | | |
NCT03758287: Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative |
|
|
| Active, not recruiting | 1/2 | 158 | RoW | CT053PTSA, Ningetinib, Gefitinib, Iressa | Sunshine Lake Pharma Co., Ltd. | Non-small Cell Lung Cancer | 07/23 | 07/23 | | |
GLORY, NCT04270591: Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer |
|
|
| Recruiting | 1/2 | 183 | Japan, US, RoW | Glumetinib, SCC244 | Haihe Biopharma Co., Ltd. | C-Met Exon 14 Mutation | 10/23 | 12/23 | | |
NCT05102006: Phase Ib/II Clinical Study of LBL-007 in Treatment of Advanced Malignant Tumors |
|
|
| Recruiting | 1/2 | 200 | RoW | LBL-007 Injection, LBL-007, Toripalimab Injection | Nanjing Leads Biolabs Co.,Ltd | Advanced Solid Tumor | 06/25 | 08/25 | | |
NCT05284994: TQ-B3525 Tablets Combined With Osimertinib Mesylate Tablets in the Treatment of Advanced Non-Small Cell Lung Cancer |
|
|
| Recruiting | 1/2 | 160 | RoW | TQ-B3525 Tablets, Osimertinib Mesylate Tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Nonsmall-cell Lung Cancer | 04/24 | 06/24 | | |
NCT05260385: To Evaluate KC1036 in the Patients with Advanced Digestive System Tumors |
|
|
| Recruiting | 1/2 | 133 | RoW | KC1036 | Beijing Konruns Pharmaceutical Co., Ltd. | Digestive System Tumors | 10/25 | 12/25 | | |
NCT05173805: Phase I Clinical Study of YL-15293 in Patients With Advanced Solid Tumor With KRAS Mutation |
|
|
| Enrolling by invitation | 1/2 | 150 | RoW | YL-15293 | Shanghai YingLi Pharmaceutical Co. Ltd. | Advanced Solid Tumor | 04/24 | 12/24 | | |
| Recruiting | 1/2 | 134 | US, RoW | PRO1160 | ProfoundBio US Co. | Renal Cell Carcinoma, Nasopharyngeal Carcinoma, Non Hodgkin Lymphoma | 11/26 | 03/27 | | |
NCT05824455: A Clinical Study of IMP4297 Capsule (JS109) Combined With Irinotecan in the Treatment of Advanced Malignant Solid Tumors |
|
|
| Terminated | 1/2 | 4 | RoW | JS109 combine with irinotecan | Shanghai Jun Pai Ying Shi Therapeutics Co., Ltd., Sponsor GmbH | Advanced Solid Tumors | 09/23 | 09/23 | | |
| Recruiting | 1/2 | 490 | RoW | LBL-007 Injection, LBL-007, Tislelizumab Injection, Tislelizumab, Cisplatin Injection, Cisplatin, Gemcitabine Hydrochloride for Injection, Gemcitabine Hydrochloride, Docetaxel injection, Docetaxel | Nanjing Leads Biolabs Co.,Ltd | Malignant Tumors | 10/25 | 12/25 | | |
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies |
|
|
| Recruiting | 1/2 | 1300 | Canada, US, RoW | SKB264 | Klus Pharma Inc. | Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer | 08/25 | 07/26 | | |
NCT06712680: A Phase I/II Study of HYP-6589 Monotherapy in Treating Advanced Solid Tumors and in Combination With Tyrosine Kinase Inhibitors in Treating Patients With Advanced NSCLC Positive for Driver Genes |
|
|
| Recruiting | 1/2 | 115 | RoW | Test Product HYP-6589 | Sichuan Huiyu Pharmaceutical Co., Ltd | Solid Tumor | 07/26 | 07/26 | | |
NCT06735144: Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors |
|
|
| Recruiting | 1/2 | 200 | RoW | FH-006 | Jiangsu HengRui Medicine Co., Ltd. | Malignant Solid Tumor | 12/27 | 12/27 | | |
NCT05435248: Phase 1/2 Study of HS-10375 in Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC) |
|
|
| Recruiting | 1/2 | 354 | RoW | HS-10375 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Advanced or Metastatic NSCLC | 03/25 | 03/26 | | |
NCT05869240: BPB-101 in Subjects With Metastatic or Locally Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 388 | RoW | BPB-101 | Betta Pharmaceuticals Co., Ltd. | Solid Tumor | 08/25 | 09/25 | | |
NCT06114511: A Study of BL-M07D1 in Patients With HER2-mutated, Locally Advanced or Metastatic Non-small-cell Lung Cancer |
|
|
| Recruiting | 1/2 | 58 | RoW | BL-M07D1 | Sichuan Baili Pharmaceutical Co., Ltd. | Non-small Cell Lung Cancer | 04/26 | 04/26 | | |
KEYNOTE F19, NCT06022757: Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments |
|
|
| Recruiting | 1/2 | 204 | RoW | XNW5004, KEYTRUDA® (pembrolizumab) 25 mg/mL Solution for Injection | Evopoint Biosciences Inc., Merck Sharp & Dohme LLC | Carcinoma, Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma, Prostate Cancer, Small-cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer, Other Solid Tumors | 08/28 | 08/28 | | |
NCT03733951: KN046 in Subjects With Advanced Solid Tumors and Lymphoma |
|
|
| Completed | 1a/1b | 139 | RoW | KN046 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Advanced Solid Tumors, Lymphoma | 01/23 | 02/23 | | |
| Active, not recruiting | 1b | 419 | RoW | QL1706 injection, PSB205 injection | Qilu Pharmaceutical Co., Ltd. | Advanced Solid Tumors | 12/21 | 12/23 | | |
NCT02959619: Ensartinib in Non-small Cell Lung Cancer Patients With Positive ALK |
|
|
| Completed | 1 | 48 | RoW | Ensartinib, X-396 | Betta Pharmaceuticals Co., Ltd. | Solid Tumor, Non-Small Cell Lung Cancer Metastatic | 10/19 | 04/20 | | |
| Not yet recruiting | 1 | 30 | NA | TQB2450, Anlotinib | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Lung Cancer | 10/20 | 12/20 | | |
NCT04390984: Drug-drug Interaction Study of Gefitinb on Apatinib in NSCLC Patients |
|
|
| Recruiting | 1 | 22 | RoW | Apatinib Mesylate, Gefitinib | Jiangsu HengRui Medicine Co., Ltd. | NSCLC | 02/21 | 03/21 | | |
NCT04296994: A Study of QL1706 in Subjects With Advanced Malignant Tumor |
|
|
| Active, not recruiting | 1 | 99 | RoW | QL1706, PSB205 | Qilu Pharmaceutical Co., Ltd. | Advanced Malignant Tumor | 12/21 | 12/23 | | |
NCT04448379: Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Cancer |
|
|
| Recruiting | 1 | 48 | RoW | JMT101, Afatinib or Osimertinib | Shanghai JMT-Bio Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Locally Advanced or Metastatic Non-Small Cell Lung Cancer | 12/21 | 06/22 | | |
NCT06128148: Phase I Study of JYP0322 in ROS1 Fusion-Positive Solid Tumors |
|
|
| Recruiting | 1 | 54 | RoW | JYP0322 50 mg qd, JYP0322 100 mg qd, JYP0322 200 mg qd, JYP0322 100 mg bid, JYP0322 150 mg bid, JYP0322 200 mg bid | Guangzhou JOYO Pharma Co., Ltd | Protein Kinase Inhibitors, Other Protocol Specified Criteria, Lung Neoplasms, Brain Neoplasms | 06/26 | 12/27 | | |
NCT04397926: Phase I Study of Individualized Neoantigen Peptides in the Treatment of EGFR Mutant Non-small Cell Lung Cancer |
|
|
| Recruiting | 1 | 20 | RoW | Individualized neoantigen peptides vaccine, HJ-N-001 | Sun Yat-sen University, Tianjin Hengjia Biotechnology Development co., LTD | Non Small Cell Lung Cancer | 05/22 | 12/22 | | |
NCT05028556: A Trial of Y101D, a PD-L1/TGF-β Bispecific Antibody, in Patients With Metastatic or Locally Advanced Solid Tumors |
|
|
| Active, not recruiting | 1 | 126 | RoW | Cohort 1 of Y101D, Cohort 2 of Y101D, Cohort 3 of Y101D, Cohort 4 of Y101D, Cohort 5 of Y101D | Wuhan YZY Biopharma Co., Ltd. | Metastatic or Locally Advanced Solid Tumors | 03/24 | 08/24 | | |
NCT05429398: A Study of Linperlisib Combination With Camrelizumab in Patients With Solid Tumor |
|
|
| Not yet recruiting | 1 | 118 | NA | Linperlisib Tablet, Camrelizumab for Injection | Shanghai YingLi Pharmaceutical Co. Ltd. | Advanced Solid Tumor | 08/23 | 05/24 | | |
NCT04603287: A Study of SI-B001, an EGFR/HER3 Bispecific Antibody, in Locally Advanced or Metastatic Epithelial Tumors |
|
|
| Recruiting | 1 | 60 | RoW | SI-B001 | Sichuan Baili Pharmaceutical Co., Ltd., SystImmune Inc. | Locally Advanced or Metastatic Epithelial Tumor | 06/25 | 06/25 | | |
| Recruiting | 1 | 96 | RoW | BL-B01D1 | Sichuan Baili Pharmaceutical Co., Ltd., SystImmune Inc. | Locally Advanced or Metastatic Solid Tumor | 06/25 | 12/25 | | |
NCT05105971: Assessment of Safety and Preliminary Efficacy With BAT6026 in Solid Tumor Patients in China |
|
|
| Active, not recruiting | 1 | 30 | RoW | BAT6026, anti-OX40 monoclonal antibody | Bio-Thera Solutions | Advanced Solid Tumors | 11/23 | 11/24 | | |
| Active, not recruiting | 1 | 7 | RoW | TQB3602 Capsule + AK105 Injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Cancers | 12/23 | 05/24 | | |
NCT05405621: Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BAT8009 |
|
|
| Recruiting | 1 | 48 | RoW | BAT8009 for Injection, Recombinant Humanized Anti-B7H3 Monoclonal Antibody-Exatecan Conjugate | Bio-Thera Solutions | Locally Advanced/Metastatic Solid Tumours | 12/23 | 12/24 | | |
NCT05441956: TGRX-326 Chinese Phase I for Advanced Non-small Cell Lung Cancer (NSCLC) |
|
|
| Active, not recruiting | 1 | 198 | RoW | TGRX-326 | Shenzhen TargetRx, Inc., Sun Yat-sen University | Non-small Cell Lung Cancer | 08/25 | 10/25 | | |
NCT05767060: BAT7104 Injection in Patients with Advanced Malignant Tumors. |
|
|
| Recruiting | 1 | 42 | RoW | BAT7104 injection, Recombinant anti-PD-L1/CD47 bispecific antibody injection | Bio-Thera Solutions, Sun Yat-sen University | Advanced Malignant Tumor | 12/24 | 12/24 | | |
| Recruiting | 1 | 150 | RoW | TQB2922 for injection | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Advanced Cancer | 12/24 | 12/25 | | |
NCT06169579: An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of ND-003 in Patients With Advanced Solid Cancers |
|
|
| Enrolling by invitation | 1 | 96 | RoW | ND-003 tablets, ND003 tablets | Shenzhen NewDEL Biotech, Co., Ltd, Shenzhen Innovation Center for Small Molecule Drug Discovery Co., Ltd., Sun Yat-sen University | Advanced Solid Tumor | 12/25 | 06/26 | | |
NCT06307925: A Phase I Study to Evaluate the Safety, Pharmacokinetics and Antitumor Activity of HC010 in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 122 | RoW | HC010 | HC Biopharma Inc. | Advanced Solid Tumor | 12/25 | 12/25 | | |
NCT05621525: Phase I Study of the BBP-398 in Patients With Advance Solid Tumors |
|
|
| Terminated | 1 | 7 | RoW | BBP-398, IACS-15509 | LianBio LLC | Advanced Solid Tumor, Advanced or Metastatic Non-small Cell Lung Cancer | 03/24 | 03/24 | | |
NCT04965220: HLX208 (BRAF V600E Inhibitor) in Combination With Trametinib in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 220 | RoW | HLX 208, trametinib | Shanghai Henlius Biotech | Solid Tumor | 06/24 | 06/25 | | |
| Recruiting | 1 | 21 | RoW | BL-B16D1 | Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Solid Tumor | 07/26 | 07/26 | | |
TQB2928-Ib-03, NCT06585059: Clinical Trial of TQB2928 in Combination With a Third-Generation Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) in Patients With Advanced Non-Small Cell Lung Cancers |
|
|
| Not yet recruiting | 1 | 20 | RoW | TQB2928 injection + Almonertinib Mesilate Tablets | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Advanced Non-small Cell Lung Cancer | 12/25 | 12/26 | | |
NCT04001777: A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients |
|
|
| Recruiting | 1 | 80 | RoW | APG-1252, APG-1252 for injection, Osimertinib Mesylate Tablets, AZD9291 | Ascentage Pharma Group Inc., Suzhou Yasheng Pharmaceutical Co., Ltd. | EGFR Positive Non-small Cell Lung Cancer | 12/24 | 06/25 | | |
NCT03917043: APG-2449 in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 150 | RoW | APG-2449, APG-2449 Capsule | Ascentage Pharma Group Inc., Suzhou Yasheng Pharmaceutical Co., Ltd. | Advanced Solid Cancer, Non Small Cell Lung Cancer, Esophageal Cancer, Ovarian Cancer, Malignant Pleural Mesothelioma | 01/25 | 02/25 | | |
NCT06032936: BBP-398 in Combination With Osimertinib in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutations |
|
|
| Terminated | 1 | 4 | RoW | BBP-398, IACS-15509, osimertinib | LianBio LLC | NSCLC | 03/24 | 03/24 | | |
BIOSG-BRG-01, NCT05864924: A Phase 1 Study of BRG01 in Subjects With Relapsed/Metastatic Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma |
|
|
| Completed | 1 | 14 | RoW | Cohort A: 3.0x10^6 CAR-T cells/kg, Cohort B: 9.0x10^6CAR-T cells/kg, Cohort C:1.5x10^7 CAR-T cells /kg | BioSyngen Pte Ltd | EBV-positive Nasopharyngeal Carcinoma | 04/24 | 04/24 | | |
